Table 1 Subjects’ characteristics.
From: The role of hyaluronic acid and hyaluronidase-1 in obstructive sleep apnoea
Control (n = 40) | OSA (n = 68) | Total (n = 108) | p | |
|---|---|---|---|---|
Age (years) | 51/39–60/ | 53/47–64/ | 53/44–62/ | 0.08 |
Males (%) | 28 | 72 | 56 | < 0.01 |
BMI (kg/m2) | 24.75 ± 4.48 | 31.98 ± 5.97 | 29.30 ± 6.48 | < 0.01 |
Hypertension (%) | 38 | 71 | 58.3 | < 0.01 |
Diabetes (%) | 13 | 21 | 17.6 | 0.29 |
Dyslipidaemia (%) | 30 | 37 | 34.3 | 0.47 |
Cardiovascular disease (%) | 10 | 15 | 13 | 0.48 |
Chronic cardiac failure (%) | 5 | 12 | 9 | 0.24 |
Cardiac arrythmia (%) | 8 | 21 | 15.7 | 0.07 |
Asthma (%) | 10 | 15 | 13 | 0.48 |
COPD (%) | 5 | 9 | 7 | 0.46 |
Smokers (%) | 5 | 46 | 30.6 | < 0.01 |
Pack years | 0/0–0/ | 0/0–10/ | 0/0–5/ | < 0.01 |
SBP (mmHg) | 120/110–130/ | 132/124–138/ | 130/120–136/ | < 0.01 |
DBP (mmHg) | 70/70–80/ | 80/74–89/ | 78/70–84/ | < 0.01 |
CRP (mg/l) | 1.47/0.83–2.83/ | 3.51/1.76–8.27/ | 2.175/1.15–4.85/ | < 0.01 |
Glucose (mmol/l) | 4.6/4.2–5.2/ | 5.3/4.9–6.7/ | 5.1/4.7–6.1/ | < 0.01 |
Cholesterol (mmol/l) | 5.64 ± 1.1 | 5.45 ± 1.26 | 5.52 ± 1.20 | 0.43 |
HDL-C (mmol/l) | 1.61/1.39–1.95/ | 1.21/0.98–1.33/ | 1.33/1.14–1.63/ | < 0.01 |
LDL-C (mmol/l) | 3.39 ± 0.98 | 3.46 ± 1.05 | 3.44 ± 1.02 | 0.73 |
Triglyceride (mmol/l) | 1.13/0.88–1.39/ | 1.67/1.25–2.17/ | 1.35/1.07–1.96/ | < 0.01 |
Lipoprotein (a) (mmol/l) | 0.25/0.07–0.56/ | 0.74/0.37–0.99/ | 0.32/0.12–0.67/ | < 0.01 |
AHI (1/h) | 1.90/0.78–2.70/ | 18.1/10.3–41.5/ | 9.25/2.38–28.23/ | < 0.01 |
ODI (1/h) | 0.75/0.20–1.53/ | 15.9/8.5–33.7/ | 6.95/1.08–22.38/ | < 0.01 |
AI (1/h)* | 45.11 ± 18.85 | 48.06 ± 14.57 | 46.09 ± 17.36 | 0.65 |
SPT (min)* | 422.5/398.3–439.3/ | 451.0/404–485/ | 435.0/403.6–479.1/ | 0.04 |
TST (min)* | 381.26 ± 45.93 | 415.32 ± 62.62 | 402.27 ± 58.81 | 0.03 |
TST90% (%) | 0.0/0.0–0.8/ | 3.45/0.53–12.35/ | 0.7/0.0–6.9/ | < 0.01 |
MinSatO2 (%) | 91/89–93/ | 83/78–87/ | 87/81–91/ | < 0.01 |
ESS | 5.5/2.0–6.8/ | 6/4–9/ | 6/4–8/ | 0.02 |
